Author:
Rico H.,Arnanz F.,Revilla M.,Perera S.,Iritia M.,Villa L. F.,Arribas I.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism
Reference29 articles.
1. Goulding A, Fisher L (1991) Preventive effects of clomifene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat. J Bone Miner Res 6:1177?1181
2. Saggese G, Bertelloni S, Baroncelli GI, Pardi D, Cinquanta L (1991) Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion. J Endocrinol Invest 14: 231?236
3. Riis BJ, Christiansen C, Johansen JS, Jacobson J (1990) Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonist? J Clin Endocrinol Metab 70:920?924
4. Matta WH, Shaw RW, Hesp R, Katz D (1987) Hypogonadism induced by luteinising hormone-releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 294:1523?1524
5. Cann CE, Henzl M, Burry K, Andreyko J, Hanson F, Adamson GD, Trobough G, Henrichs L, Stewart G (1987) Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn DV, Martin TJ, Meunier JP (eds) Calcium regulation and bone metabolism, vol 9. Excerpta Medica, Amsterdam, pp 123?127
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献